Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)
A Multi-center, Randomized, Assessor-blinded, Phase II, Parallel Dose-finding Trial in Subjects of ASA Class 1 - 3 to Assess the Efficacy and Safety of 5 Doses of Org 25969 When Administered at 1-2 PTCs After Administration of Zemuron®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has an ASA Class of 1 to 3
- Is scheduled for surgical procedures (excluding dental and neck surgeries) with an anticipated duration of anesthesia of ≥45 minutes with the use of Zemuron®
Exclusion Criteria:
- Is undergoing dental or neck surgery
- Has anatomical malformation that would impede intubation
- Has or is suspected to have neuromuscular disorders impairing neuromuscular block and/or significant renal dysfunction
- Is known or suspected to have a family history of malignant hyperthermia
- Is known or suspected to have an allergy to narcotics, muscle relaxants, or other medications used during general anesthesia
- Is pregnant
- Is a female of childbearing potential not using 1 of the following methods of birth control: condom or diaphragm with spermicide, vasectomized partner (<6 months), intrauterine device (IUD), or abstinence
- Is breast-feeding
- Has already participated in the study
- Has participated in another clinical trial, not pre-approved by Organon Pharmaceuticals USA within 30 days of entering this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced neuromuscular blockade (NMB) reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
|
EXPERIMENTAL: 10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session.
MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
|
MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion.
Doses are based on actual body weight.
Other Names:
Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs.
If needed, a maintenance dose of 0.15 mg/kg will be given.
Doses are based on actual body weight.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time From Start of Administration of MK-8616 to Recovery T4/T1 Ratio to 0.9
Time Frame: Up to 90 minutes
|
The mean time from the start of MK-8616 administration to recovery T4/T1 ratio of 0.9 was determined.
Less time indicates faster recovery from NMB.
The ratio of T4 (fourth twitch; amplitude of fourth response to train of four [TOF] stimulation is expressed as percent of control T4) over T1 (first twitch; amplitude of first response to TOF stimulation is expressed as percent of control T1) ranges from 0 (complete loss of T4 twitch response) to 1.0 (complete recovery of T4 twitch response).
For TOF stimulation, 4 consecutive square wave supra-maximal stimuli of 0.2 msec duration were delivered at 2 Hz every 15 seconds.
Neuromuscular monitoring was performed with the TOF-Watch® SX.
|
Up to 90 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Experiencing ≥1 Adverse Events (AEs)
Time Frame: Up to 7 days following MK-8616 administration
|
The percentage of participants experiencing ≥1 AEs was determined.
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment.
|
Up to 7 days following MK-8616 administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P06387
- MK-8616-042 (OTHER: Merck Protocol Number)
- 19.4.204 (OTHER: Organon Protocol Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.